Danaher Co. (NYSE:DHR) Shares Purchased by Dash Acquisitions Inc.

Dash Acquisitions Inc. boosted its position in Danaher Co. (NYSE:DHR) by 1.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 62,778 shares of the conglomerate’s stock after purchasing an additional 960 shares during the quarter. Danaher comprises about 4.7% of Dash Acquisitions Inc.’s holdings, making the stock its 8th largest position. Dash Acquisitions Inc.’s holdings in Danaher were worth $15,028,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Cape Investment Advisory Inc. acquired a new position in shares of Danaher during the 4th quarter valued at about $25,000. Tsfg LLC increased its stake in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. BKM Wealth Management LLC acquired a new position in shares of Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. acquired a new position in shares of Danaher during the 4th quarter valued at about $29,000. Finally, Rakuten Securities Inc. purchased a new stake in shares of Danaher during the 4th quarter worth about $36,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Insiders have sold 148,783 shares of company stock valued at $37,536,717 over the last three months. Company insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of research reports. Barclays boosted their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Jefferies Financial Group started coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target for the company. TD Cowen upped their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday. Finally, Robert W. Baird upped their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $268.67.

Danaher Stock Performance

Shares of DHR stock traded down $4.10 on Tuesday, hitting $240.41. 5,062,756 shares of the stock traded hands, compared to its average volume of 2,876,070. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The company has a market capitalization of $178.07 billion, a PE ratio of 40.68, a PEG ratio of 3.82 and a beta of 0.84. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11. The company’s fifty day moving average is $256.13 and its 200 day moving average is $246.86.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period in the prior year, the company posted $2.36 EPS. The business’s revenue was down 2.6% compared to the same quarter last year. On average, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.